Liquid Genomics liquidgenomics.com


Public list: Medical Devices (5945) Genomics (474)

Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.

Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.

Company (Alive / Active)

Phone: 626-893-4123

Fax:

1725 Del Amo Blvd

Torrance, 90501
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Liquid Genomics $4.9M Jun 27, 2016
See all 4 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Liquid Genomics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

20/20 GeneSystems

Rockville, Maryland, United States
Alive / Active20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.Login to see details

Guardant Health

Redwood City, California, United States
Alive / ActiveGuardant Health has developed genomic cancer testing from a single blood draw, helping oncologists learn accurate and actionable information about patients, while avoiding the costs and risks of tissue biopsies. The genomic test helps match advanced-cancer patients to approved targeted therapies as well as drugs in clinical trials.Login to see details
See all 4 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)